Skip to content

Pharmaceuticals

ISSN 1424-8247

72 papers in the library · 565 citations · publishing 2011-2026

Papers

Sort Most recent Most cited

Extraction Yields of Psilocybin and Psilocin: A Short Review of Current Methods and Their Implications

Pharmaceuticals March 7, 2025 Taynah P Galdino, Lucas C Oliveira, Mateus A Luz et al. 11 citations

The growing body of evidence supporting the therapeutic efficacy of psychoactive substances, like psilocybin, has driven significant interest in recent decades due to their low toxicity and potential applications in treating various mental health disorders. However, producing pharmaceutical-grade psilocybin remains challenging, with three primary approaches: chemical synthesis, biosynthesis,...

DOI: 10.3390/ph18030380 (opens in new tab) Extraction methods Psychoactive compounds Yield optimization Extraction techniques +3

Long-Term Cognitive Outcomes of Esketamine Nasal Spray in Treatment-Resistant Depression: A Preliminary Report.

Pharmaceuticals January 27, 2025 Matildes de Freitas Menezes Sobreiro, Paulo Sergio Panse Silveira, Vitor Breseghello Cavenaghi et al. 5 citations

Background/Objectives: Ketamine/esketamine has a rapid/robust antidepressant effect on treatment-resistant depression (TRD). However, its long-term cognitive effects remain unclear. In this study, we investigated the potential cognitive effects of an esketamine spray on a series of TRD patients. Methods: We evaluated the cognitive performance of eight TRD patients subjected to an esketamine...

DOI: 10.3390/ph18020173 (opens in new tab) Full text (opens in new tab) Long term Treatment-resistant depression trd Refractory depression Cognitive function +2

Demystifying the Antidepressant Mechanism of Action of Stinels, a Novel Class of Neuroplastogens: Positive Allosteric Modulators of the NMDA Receptor.

Pharmaceuticals January 24, 2025 John E Donello, Roger S McIntyre, Donald B Pickel et al. 14 citations

Plastogens are a class of therapeutics that function by rapidly promoting changes in neuroplasticity. A notable example, ketamine, is receiving great attention due to its combined rapid and long-term antidepressant effects. Ketamine is an N-methyl-D-aspartate receptor (NMDAR) antagonist, and, in addition to its therapeutic activity, it is associated with psychotomimetic and dissociative side...

Uncovering Psychedelics: From Neural Circuits to Therapeutic Applications

Pharmaceuticals January 19, 2025 Marco Bonaso, Letizia Biso, Benedetta Zucchini et al. 13 citations

Psychedelics, historically celebrated for their cultural and spiritual significance, have emerged as potential breakthrough therapeutic agents due to their profound effects on consciousness, emotional processing, mood, and neural plasticity. This review explores the mechanisms underlying psychedelics’ effects, focusing on their ability to modulate brain connectivity and neural circuit activity,...

Effects of Ketamine vs. Midazolam in Adolescent Treatment Resistant Depression.

Pharmaceuticals December 4, 2024 Andrea Macejova, Veronika Kovacova, Ingrid Tonhajzerova et al. 7 citations

Background: Adolescent treatment resistant depression (TRD) is increasing in recent years. While ketamine showed rapid antidepressant effects in adult TRD studies, research on its effectiveness in adolescents is limited. Methods: This study examines the effects of intravenous ketamine vs. midazolam on depressive and anxiety symptomatology assessed by the Montgomery-Åsberg Depression Rating...

Therapeutic Potential of Psychedelic Compounds for Substance Use Disorders.

Pharmaceuticals November 5, 2024 Tamara Valdez, Valbhi Patel, Nattaphone Senesombath et al. 4 citations

Psychedelics have recently (re)emerged as therapeutics of high potential for multiple mental health conditions, including substance use disorders (SUDs). Despite early mid-20th century anecdotal reports and pilot studies demonstrating the possibility of these substances in efficaciously treating conditions such as alcohol and opioid use disorders, legal restrictions and social stigma have...

Use of Ketamine in Patients with Multifactorial Neuropathic Pain: A Systematic Review and Meta-Analysis.

Pharmaceuticals September 3, 2024 Alejandro Bruna-Mejias, Vicente Baeza, Javiera Gamboa et al. 4 citations

Neuropathic pain (NP) is a heterogeneous group of conditions characterized by the experience of a number of sensory disturbances including pain, burning sensations, paroxysms of stabbing pain, dysesthesias, allodynia, and hyperalgesia. The above-mentioned sensations may occur in a specific dermatome area or other delimited region of the body. The objective of this review was to analyze the...

DOI: 10.3390/ph17091165 (opens in new tab) Full text (opens in new tab) Pharmacology Chronic pain Neuropathic pain/nerve pain/neuralgia/polyneuropathy Ketamine/ketalar/special k +2

A Multi-Center, Open-Label, Single-Arm Study to Investigate the Early Effectiveness of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Using a Mobile Self-Monitoring Application.

Pharmaceuticals August 30, 2024 Junhyung Kim, Seung-Hoon Lee, Cheolmin Shin et al. 8 citations

This study assesses the early effectiveness of esketamine nasal spray (ESK) in adults with treatment-resistant depression (TRD) 1 day after the first administration, as monitored through self-assessment via the mobile application, Esketamine Continuing Assessment for Relapse Prevention (EsCARe). In this multi-center, open-label, single-arm study, adults aged 18-65 years diagnosed with TRD after...

Examining the Role of Oxytocinergic Signaling and Neuroinflammatory Markers in the Therapeutic Effects of MDMA in a Rat Model for PTSD.

Pharmaceuticals June 27, 2024 Haron Avgana, Roni Shira Toledano, Irit Akirav 8 citations

MDMA-assisted psychotherapy has shown potential as an effective treatment for post-traumatic stress disorder (PTSD). Preclinical studies involving rodents have demonstrated that MDMA can facilitate the extinction of fear memories. It has been noted that MDMA impacts oxytocin neurons and pro-inflammatory cytokines. Thus, the aim of this study was to explore the role of oxytocinergic signaling...

Efficacy and Safety of Pharmacological Treatment in Patients with Complex Regional Pain Syndrome: A Systematic Review and Meta-Analysis.

Pharmaceuticals June 20, 2024 He Zhu, Bei Wen, Jijun Xu et al. 15 citations

Complex regional pain syndrome (CRPS) is a disabling condition that usually affects the extremities after trauma or surgery. At present, there is no FDA-approved pharmacological treatment for patients with CRPS. We performed this systematic review and meta-analysis to evaluate the efficacy and safety of pharmacological therapies and determine the best strategy for CRPS. We searched the...

DOI: 10.3390/ph17060811 (opens in new tab) Full text (opens in new tab) Pain relief Pharmacological treatment Chronic pain Pain management +6

The Role of Ayahuasca in Colorectal Adenocarcinoma Cell Survival, Proliferation and Oxidative Stress.

Pharmaceuticals June 2, 2024 Joana Gonçalves, Mariana Feijó, Sílvia Socorro et al.

The psychedelic beverage ayahuasca is originally obtained by Banisteriopsis caapi (B. caapi) (BC) and Psychotria viridis (P. viridis) (PV). However, sometimes these plant species are replaced by others that mimic the original effects, such as Mimosa hostilis (M. hostilis) (MH) and Peganum harmala (P. harmala) (PH). Its worldwide consumption and the number of studies on its potential therapeutic...

Ketamine's Amelioration of Fear Extinction in Adolescent Male Mice Is Associated with the Activation of the Hippocampal Akt-mTOR-GluA1 Pathway.

Pharmaceuticals May 22, 2024 Emilija Glavonic, Milorad Dragic, Milos Mitic et al. 5 citations

Fear-related disorders, including post-traumatic stress disorder (PTSD), and anxiety disorders are pervasive psychiatric conditions marked by persistent fear, stemming from its dysregulated acquisition and extinction. The primary treatment for these disorders, exposure therapy (ET), relies heavily on fear extinction (FE) principles. Adolescence, a vulnerable period for developing psychiatric...

DOI: 10.3390/ph17060669 (opens in new tab) Full text (opens in new tab) Ketamine Adolescence Fear extinction Fear-related disorders +7

3-Methoxy-Phencyclidine Induced Psychotic Disorder: A Literature Review and an 18F-FDG PET/CT Case Report.

Pharmaceuticals March 31, 2024 Maria Pepe, Marco Di Nicola, Fabrizio Cocciolillo et al. 6 citations

New Psychoactive Substances (NPS) are modifying the drug scenario worldwide and have become a public health concern because of their toxicological profiles and their harmful physical/psychological effects. 3-Methoxy-Phencyclidine (3-MeO-PCP), a non-competitive antagonist of glutamate N-methyl-D-aspartate (NMDA) receptors, belongs to the phencyclidine-like subfamily of arylcyclohexylamines and...

DOI: 10.3390/ph17040452 (opens in new tab) Full text (opens in new tab) 3-meo-pcp Nps Cognitive functioning Neuroimaging +1

Effect of Acute Ketamine Treatment on Sympathetic Regulation Indexed by Electrodermal Activity in Adolescent Major Depression.

Pharmaceuticals March 10, 2024 Veronika Kovacova, Andrea Macejova, Ingrid Tonhajzerova et al. 4 citations

Ketamine is a potential rapid-onset antidepressant characterized by sympathomimetic effects. However, the question of ketamine's use in treating adolescents' major depressive disorder (MDD) is still discussed. Thus, we aimed to study the acute effect of ketamine infusion treatment on sympathetic regulation using electrodermal activity (EDA) in addition to an assessment of depressive...

DOI: 10.3390/ph17030358 (opens in new tab) Full text (opens in new tab) Major depressive disorder Adolescence Depressive symptomatology Electrodermal activity +12

Unique Effects of (R)-Ketamine Compared to (S)-Ketamine on EEG Theta Power in Rats.

Pharmaceuticals February 1, 2024 Dóra Pothorszki, Szabolcs Koncz, Dóra Török et al. 7 citations

Differences in the pharmacological effects of (S)-ketamine and (R)-ketamine are at the focus of research. Clinical data and our rat studies confirmed the antidepressant effect of (S)- but not (R)-ketamine, with similar differences in quantitative electroencephalogram (EEG) and sleep effects. In contrast, studies mainly on mice showed some stronger, preferable effects of (R)-ketamine. EEG theta...

Ketamine, an Old–New Drug: Uses and Abuses

Pharmaceuticals December 21, 2023 Katarina Savić Vujović, Ana Jotić, Branislava Medić et al. 32 citations

Ketamine as an old-new drug has a variety of clinical implications. In the last 30 years, ketamine has become popular for acute use in humans. Ketamine in standard doses is principally utilized for the induction and maintenance of surgical procedures. Besides its use in anesthesia and analgesia, recent studies have shown that ketamine has found a place in the treatment of asthma, epilepsy,...

Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression.

Pharmaceuticals November 7, 2023 Courtney M Vecera, Alan C. Courtes, Gregory Jones et al.

Treatment-resistant depression (TRD) is a term used to describe a particular type of major depressive disorder (MDD). There is no consensus about what defines TRD, with various studies describing between 1 and 4 failures of antidepressant therapies, with or without electroconvulsive therapy (ECT). That is why TRD is such a growing concern among clinicians and researchers, and it explains the...

Unraveling the In Vitro Toxicity Profile of Psychedelic 2C Phenethylamines and Their N-Benzylphenethylamine (NBOMe) Analogues

Pharmaceuticals August 15, 2023 Daniel Martins, Eva Gil-Martins, Fernando Cagide et al. 13 citations

Mescaline derivative (2C phenethylamines) drugs have been modified by the introduction of a N-2-methoxybenzyl group to originate a new series of compounds with recognized and potent psychedelic effects, the NBOMe-drugs. Although they are prevalent in unregulated drug markets, their toxicity profile is still poorly understood, despite several reports highlighting cases of acute intoxication,...

DOI: 10.3390/ph16081158 (opens in new tab) 2c drugs Hepg2 cells Nbome drugs Sh-sy5y cells +14

Efficacy of Ketamine with and without Lamotrigine in Treatment-Resistant Depression: A Preliminary Report

Pharmaceuticals August 1, 2023 Boney Joseph, Nicolas A. Nunez, Simon Kung et al. 14 citations

Intravenous (IV) ketamine and FDA-approved intranasal (IN) esketamine are increasingly used for treatment-resistant depression (TRD). Preliminary studies have suggested a synergistic effect of ketamine and lamotrigine, although the data are inconclusive. Herein, we report the response to serial ketamine/esketamine treatment among patients with TRD with or without lamotrigine therapy. In this...

Exploring the Molecular Targets for the Antidepressant and Antisuicidal Effects of Ketamine Enantiomers by Using Network Pharmacology and Molecular Docking

Pharmaceuticals July 17, 2023 Glorister A. Altê, Ana Lúcia S Rodrigues 17 citations

Ketamine, a racemic mixture of esketamine (S-ketamine) and arketamine (R-ketamine), has received particular attention for its rapid antidepressant and antisuicidal effects. NMDA receptor inhibition has been indicated as one of the main mechanisms of action of the racemic mixture, but other pharmacological targets have also been proposed. This study aimed to explore the possible multiple targets...

DOI: 10.3390/ph16071013 (opens in new tab) Ketamine Kegg Antidepressant Computational biology +7

Infoveillance and Critical Analysis of the Systematically Reviewed Literature on Dimethyltryptamine and the "God Molecule".

Pharmaceuticals June 2, 2023 Ahmed Al-Imam, Marek A Motyka, Beata Hoffmann et al. 6 citations

Aboriginals of Latin America have used DMT (N,N-dimethyltryptamine) in ritualistic ceremonies for centuries. Nevertheless, there are limited data on web users' interest concerning DMT. We aim to review the literature and explore the spatial-temporal mapping of online search behavior concerning DMT, 5-MeO-DMT, and the Colorado River toad via Google Trends over the past 10 years (2012-2022) while...

DOI: 10.3390/ph16060831 (opens in new tab) Full text (opens in new tab) Incilius alvarius 5-Methoxy-N,N-Dimethyltryptamine Colorado river toad Sonoran desert toad +4

NMDA Receptor Glycine Binding Site Modulators for Prevention and Treatment of Ketamine Use Disorder.

Pharmaceuticals May 30, 2023 Yu-Chin Hsiao, Mei-Yi Lee, Ming‐huan Chan et al.

Ketamine offers a fast-acting approach to relieving treatment-resistant depression, but its abuse potential is an issue of concern. As ketamine is a noncompetitive N-methyl-D-aspartate receptor (NMDAR) ion channel blocker, modulation of NMDAR might be an effective strategy to counteract the abuse liability of ketamine and even to treat ketamine use disorder. This study evaluated whether NMDAR...

DOI: 10.3390/ph16060812 (opens in new tab) Full text (opens in new tab) D-serine Breakpoint Reinstatement Sarcosine +1

Ketamine and the Disinhibition Hypothesis: Neurotrophic Factor-Mediated Treatment of Depression.

Pharmaceuticals May 12, 2023 Philip Borsellino, Reese I. Krider, Deanna Chea et al.

Ketamine is a promising alternative to traditional pharmacotherapies for major depressive disorder, treatment-resistant depression, and other psychiatric conditions that heavily contribute to the global disease burden. In contrast to the current standard of care medications for these disorders, ketamine offers rapid onset, enduring clinical efficacy, and unique therapeutic potential for use in...

Pharmacological Mechanism of Ketamine in Suicidal Behavior Based on Animal Models of Aggressiveness and Impulsivity: A Narrative Review.

Pharmaceuticals April 21, 2023 Thi Mai Loan Nguyen, Fabrice Jollant, Laurent Tritschler et al.

Around 700,000 people die from suicide each year in the world. Approximately 90% of suicides have a history of mental illness, and more than two-thirds occur during a major depressive episode. Specific therapeutic options to manage the suicidal crisis are limited and measures to prevent acting out also remain limited. Drugs shown to reduce the risk of suicide (antidepressants, lithium, or...

Benzydamine-An Affordable Over-the-Counter Drug with Psychoactive Properties-From Chemical Structure to Possible Pharmacological Properties.

Pharmaceuticals April 10, 2023 Bianca-Eugenia Ősz, George Jîtcă, Andreea Sălcudean et al. 29 citations

Benzydamine is a non-steroidal anti-inflammatory drug with distinct pharmacological properties from other compounds in the same therapeutic class. The differences are structural and pharmacological in nature; the anti-inflammatory mechanism is not strictly explained by the ability to interfere with the synthesis of prostaglandins. The compound is used strictly in local inflammatory diseases...

DOI: 10.3390/ph16040566 (opens in new tab) Full text (opens in new tab) Benzydamine Inflammation Neuropathic pain Over the counter +6